Sign In
Buy TGTX
$53.94
-0.460 (-0.85%)
At Close: Jun 23, 2026
TG Therapeutics Stock Rises Thursday: What's Driving The Gains?
03:29pm, Thursday, 18'th Jun 2026
TG Therapeutics Inc. (NASDAQ:TGTX) shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.
TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing
08:00am, Wednesday, 17'th Jun 2026
TG Therapeutics stock is on an absolute rampage, climbing 70% in roughly the first six months of the year, as the biotech takes on Roche.
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
06:16am, Thursday, 11'th Jun 2026
TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more str
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
10:21am, Wednesday, 10'th Jun 2026
TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.
TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
05:12pm, Tuesday, 09'th Jun 2026
TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed
Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?
12:35pm, Friday, 05'th Jun 2026
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?
TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi
12:01pm, Thursday, 04'th Jun 2026
TG Therapeutics jumps 9.5% after phase I data show that subcutaneous Briumvi achieved over 60% bioavailability, sustained drug exposure, and was well tolerated.
TG Therapeutics: Phase 1 Results Of Subcutaneous Briumvi Are A De-Risking Event
09:00am, Thursday, 04'th Jun 2026
TG Therapeutics, Inc.'s Phase 1 results of subcutaneous Briumvi are a major de-risking event for TG's most important clinical development program. SC Briumvi's bioavailability, safety, and tolerabilit
TG Therapeutics Stock Surges After Drug Trial Update
03:19pm, Wednesday, 03'rd Jun 2026
Shares of TG Therapeutics Inc (NASDAQ:TGTX) are climbing Wednesday afternoon following the release of early-stage clinical trial data for a new formulation of its multiple sclerosis drug, BRIUMVI. Her
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
07:30am, Wednesday, 03'rd Jun 2026
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
07:30am, Tuesday, 02'nd Jun 2026
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Gold
Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no evi
TG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 Outlook
01:35pm, Thursday, 28'th May 2026
TG Therapeutics remains a "Strong Buy" as BRIUMVI drives robust revenue growth and pipeline expansions. The company raised 2026 BRIUMVI sales guidance to $885–$900 million, reflecting 63% year-over-
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study
11:35am, Thursday, 28'th May 2026
TG Therapeutics announces that Briumvi's late-stage ENHANCE study met its goal, supporting a potential single-infusion regimen for relapsing MS patients.
